Tilray (TLRY) Competitors $0.86 -0.01 (-0.77%) As of 10:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TLRY vs. CRON, MNMD, USNA, SNDL, CDXC, ACB, BTMD, CGC, MDWD, and FTLFShould you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), Mind Medicine (MindMed) (MNMD), USANA Health Sciences (USNA), SNDL (SNDL), ChromaDex (CDXC), Aurora Cannabis (ACB), biote (BTMD), Canopy Growth (CGC), MediWound (MDWD), and FitLife Brands (FTLF). These companies are all part of the "medicinals & botanicals" industry. Tilray vs. Cronos Group Mind Medicine (MindMed) USANA Health Sciences SNDL ChromaDex Aurora Cannabis biote Canopy Growth MediWound FitLife Brands Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Which has more risk & volatility, CRON or TLRY? Cronos Group has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Tilray has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Do analysts prefer CRON or TLRY? Cronos Group currently has a consensus target price of $3.00, indicating a potential upside of 54.64%. Tilray has a consensus target price of $2.70, indicating a potential upside of 211.17%. Given Tilray's stronger consensus rating and higher probable upside, analysts plainly believe Tilray is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Tilray 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Is CRON or TLRY more profitable? Tilray has a net margin of -30.95% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Tilray's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group-42.65% -2.56% -2.47% Tilray -30.95%-4.40%-3.57% Does the MarketBeat Community prefer CRON or TLRY? Cronos Group received 16 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.26% of users gave Tilray an outperform vote. CompanyUnderperformOutperformCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% TilrayOutperform Votes44859.26% Underperform Votes30840.74% Which has preferable earnings and valuation, CRON or TLRY? Cronos Group has higher earnings, but lower revenue than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$111.23M6.67-$73.96M-$0.13-14.92Tilray$210.48M3.87-$244.98M-$0.30-2.89 Do insiders and institutionals hold more shares of CRON or TLRY? 8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 9.4% of Tilray shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by company insiders. Comparatively, 0.9% of Tilray shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to CRON or TLRY? In the previous week, Tilray had 20 more articles in the media than Cronos Group. MarketBeat recorded 20 mentions for Tilray and 0 mentions for Cronos Group. Tilray's average media sentiment score of 0.44 beat Cronos Group's score of 0.00 indicating that Tilray is being referred to more favorably in the news media. Company Overall Sentiment Cronos Group Neutral Tilray Neutral SummaryTilray beats Cronos Group on 10 of the 18 factors compared between the two stocks. Get Tilray News Delivered to You Automatically Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLRY vs. The Competition Export to ExcelMetricTilrayMedicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$813.60M$1.19B$16.25B$9.12BDividend YieldN/AN/A2.92%3.98%P/E Ratio-2.8938.8316.5919.12Price / Sales3.875.684.87119.58Price / CashN/A10.3916.7338.24Price / Book0.211.956.865.12Net Income-$244.98M-$53.22M$709.20M$245.96M7 Day Performance-6.98%-4.82%-0.11%-0.89%1 Month Performance-25.84%-1.99%0.94%-0.51%1 Year Performance-51.25%-12.35%8.79%16.50% Tilray Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLRYTilray2.7095 of 5 stars$0.86-0.8%$2.70+213.6%-51.8%$809.20M$788.94M-2.882,650CRONCronos Group1.3106 of 5 stars$1.97-1.5%$3.00+52.3%-12.2%$753.58M$87.24M-15.15450MNMDMind Medicine (MindMed)2.3788 of 5 stars$9.89+14.3%$26.33+166.3%+61.3%$725.25MN/A-4.3840Gap UpHigh Trading VolumeUSNAUSANA Health Sciences4.2218 of 5 stars$31.73+0.4%$38.00+19.8%-34.4%$604.74M$921.01M11.211,800Upcoming EarningsAnalyst DowngradeAnalyst RevisionNews CoverageSNDLSNDL3.5607 of 5 stars$1.86flat$3.25+74.7%+29.4%$488.77M$673.33M-6.002,516CDXCChromaDex4.5002 of 5 stars$5.87+5.2%$8.00+36.3%+258.5%$448.35M$83.57M587.59120News CoverageACBAurora Cannabis0.2592 of 5 stars$6.31-4.7%N/A+68.9%$346.17M$200.35M126.231,073Gap UpBTMDbiote3.067 of 5 stars$4.58flat$10.00+118.3%+3.2%$248.88M$185.36M17.62194CGCCanopy Growth1.7939 of 5 stars$1.89flat$2.00+5.8%-54.5%$246.51M$220.27M-0.381,029MDWDMediWound1.2066 of 5 stars$18.76+0.8%$27.50+46.6%+41.8%$202.42M$18.69M-6.4780FTLFFitLife Brands4.4963 of 5 stars$15.15+0.9%$20.00+32.0%+34.8%$69.84M$52.70M8.9620 Related Companies and Tools Related Companies CRON Competitors MNMD Competitors USNA Competitors SNDL Competitors CDXC Competitors ACB Competitors BTMD Competitors CGC Competitors MDWD Competitors FTLF Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLRY) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tilray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tilray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
